Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury.
Synthetic peroxisome proliferator-activated receptor gamma (PPAR-gamma) ligands shown to induce adipocyte differentiation and increase insulin sensitivity, thiazolidinediones have recently been implicated as regulators of cellular inflammatory and ischemic responses. Thiazolidinediones inhibit the activity of a number of transcriptional factors, including nuclear factor-gammaB, activating protein 1, signal transducers and activated T cells, and early response gene 1 by either PPAR-gamma-dependent or -independent mechanisms. Recent experimental studies demonstrated a dramatic protection by thiazolidinediones against cardiac, gastrointestinal and lung injury after ischemia-reperfusion, in addition to a significant reduction in infiltrating neutrophils. These reports have hypothesized that the inhibition of neutrophil-mediated inflammation by thiazolidinediones is involved in the reduction of ischemia-reperfusion-induced tissue injury. Altogether, recent findings suggest that thiazolidinediones could represent a novel therapeutic approach to reducing or preventing reperfusion injury.